Other blood‐based markers of neurodegeneration, including SB100 and T‐tau, have also been described in AD (Olsson et al, 2016; Michetti et al, 2019); the clinical relevance of these measures has been shown to be comparatively low, however, and as such will not be covered here. The gene discussed is MAPT; the disease is Alzheimer disease.